Search Clinical Trials
By Condition
By Location (USA)
By Location (Other)
By Sponsor
Resources
Privacy Policy
About Us
Disclaimer
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma Clinical Trials Facts presented on Clinical Trials Search isn't designed to be a substitute for proven healthcare advice, calls or treatment by using a genuine medical doctor. We aren't mDs. Always confer with your doctor on Combination Chemotherapy in Treating Patients With Relapsed or Refractory Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma conditions. Clinical Trials Search.org is a website devoted to listing clinical research studies in human subjects. Combination Chemotherapy in Treating Patients With Relapsed or Refractory Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma Clinical research trials and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma healthcare trials occur in a lot of of places across the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the effectivity of new does drugs. The role of the studies / undertakings is to solve specific human healthcare questions. Clinical trials are a popular way for doctors, government agencies, and private sector companies to find treatments for all kinds of conditions, including Combination Chemotherapy in Treating Patients With Relapsed or Refractory Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma. Combination Chemotherapy in Treating Patients With Relapsed or Refractory Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma Clinical Trials and other clinical trials allow for volunteers to access health treatment choices before they are available to the general public. Many times the test subjects get treatment for without cost, and sometimes they are compensated for their time. Occasionally there is a cost for a Combination Chemotherapy in Treating Patients With Relapsed or Refractory Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma clinical trial. Test subjects typically receive the most effective healthcare possible for their Combination Chemotherapy in Treating Patients With Relapsed or Refractory Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma condition. Risks are a reality, nonetheless, and could include extra or frequent dr. calls, health hazards (perhaps life-jeopardizing), and/or the treatment being ineffective. Trials are federally regulated with rigid guidelines to protect clinical trials subjects.

Home > "C" Clinical Trials Conditions > Combination Chemotherapy in Treating Patients With Relapsed or Refractory Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma

Combination Chemotherapy in Treating Patients With Relapsed or Refractory Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma



Combination Chemotherapy in Treating Patients With Relapsed or Refractory Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma

For Condition: anaplastic large cell lymphoma,recurrent grade III follicular large cell lymphoma,recurrent adult diffuse large cell lymphoma,recurrent adult diffuse small noncleaved cell/Burkitt's lymphoma
Status: No longer recruiting
Sponsor(s): Cancer and Leukemia Group B , National Cancer Institute (NCI)
Synopsis: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining doxorubicin and topotecan in treating patients who have relapsed or refractory intermediate-grade or high-grade non-Hodgkin's lymphoma.
Details: OBJECTIVES: - Determine the response rate and time to progression in patients with relapsed or refractory intermediate or high grade non-Hodgkin's lymphoma treated with doxorubicin and topotecan. - Determine the toxicity of this regimen in these patients. OUTLINE: Patients receive doxorubicin IV over 5-10 minutes on day 1 and topotecan IV over 30 minutes on days 3-5. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression. Patients are followed every 6 months for 2 years and annually for the next 3 years. PROJECTED ACCRUAL: Approximately 55 patients will be accrued for this study over 2.5 years.
Eligibility:
Study Type:
  Interventional, Treatment
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: - Histologically confirmed recurrent or refractory non-Hodgkin's lymphoma of one of the following subtypes: - Follicular center lymphoma, grade 3 - Diffuse large B-cell lymphoma - Diffuse large B-cell lymphoma, primary mediastinal B-cell lymphoma - Burkitt's lymphoma - High grade B-cell lymphoma, Burkitt-like - Anaplastic large cell lymphoma, CD30+ cell type - Anaplastic large cell lymphoma, T-cell type - Anaplastic large cell lymphoma, null-cell type - Anaplastic large cell lymphoma, Hodgkin's like - Bidimensionally measurable disease NOTE: A new classification scheme for adult non-Hodgkin's lymphoma has been adopted by PDQ. The terminology of "indolent" or "aggressive" lymphoma will replace the former terminology of "low", "intermediate", or "high" grade lymphoma. However, this protocol uses the former terminology. PATIENT CHARACTERISTICS: Age: - Any age Performance status: - Not specified Life expectancy: - Not specified Hematopoietic: - Absolute neutrophil count at least 1,500/mm3 - Platelet count at least 100,000/mm3 Hepatic: - Bilirubin no greater than 2.0 mg/dL history of Gilbert's Disease - AST no greater than 2.5 times upper limit of normal Renal: - Creatinine normal Cardiovascular: - LVEF at least 45% by MUGA or echocardiogram Other: - Not pregnant or nursing - Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic therapy: - Not specified Chemotherapy: - Greater than 3 weeks since prior chemotherapy (6 weeks since prior nitrosoureas or mitomycin) - No greater than 96 mg/m2 mitoxantrone - No greater than 400 mg/m2 prior doxorubicin or combined total doxorubicin and mitoxantrone - No prior camptothecins - No other concurrent chemotherapy Endocrine therapy: - No concurrent hormonal therapy except steroids for adrenal failure or hormones given for nondisease conditions (e.g., insulin for diabetes) - No concurrent dexamethasone or other steroidal antiemetics Radiotherapy: - Greater than 3 weeks since prior radiotherapy - No concurrent radiotherapy except whole brain irradiation for documented CNS disease Surgery: - Not specified
Total Enrollment: 

Location and Contact Information:

Overall Study Official:
NancyBartlett,  Study Chair,  Washington University School of Medicine

New Hanover Regional Medical Center
Wilmington,  North Carolina,  28402-9025
United States
 

Veterans Affairs Medical Center - Washington, DC
Washington D.C.,  District of Columbia,  20422
United States
 

CCOP - Southern Nevada Cancer Research Foundation
Las Vegas,  Nevada,  89106
United States
 

University of Puerto Rico School of Medicine Medical Sciences Campus
San Juan,  ,  00936-5067
Puerto Rico
 

Elmhurst Hospital Center
Elmhurst,  New York,  11373
United States
 

Veterans Affairs Medical Center - Columbia (Truman Memorial)
Columbia,  Missouri,  65201
United States
 

Virginia Oncology Associates - Norfolk
Norfolk,  Virginia,  23502
United States
 

Veterans Affairs Medical Center - Dallas
Dallas,  Texas,  75216
United States
 

Barnes-Jewish Hospital
St. Louis,  Missouri,  63110
United States
 

CCOP - Mount Sinai Medical Center
Miami,  Florida,  33140
United States
 

Louis A. Weiss Memorial Hospital
Chicago,  Illinois,  60640
United States
 

University of Nebraska Medical Center
Omaha,  Nebraska,  68198-7680
United States
 

Vermont Cancer Center
Burlington,  Vermont,  05401-3498
United States
 

Veterans Affairs Medical Center - San Diego
San Diego,  California,  92161
United States
 

Weill Medical College of Cornell University
New York City,  New York,  10021
United States
 

Veterans Affairs Medical Center - Minneapolis
Minneapolis,  Minnesota,  55417
United States
 

MBCCOP - Massey Cancer Center
Richmond,  Virginia,  23298-0037
United States
 

Veterans Affairs Medical Center - Syracuse
Syracuse,  New York,  13210
United States
 

CCOP - Southeast Cancer Control Consortium
Winston Salem,  North Carolina,  27104-4241
United States
 

Veterans Affairs Medical Center - Chicago (Westside Hospital)
Chicago,  Illinois,  60612
United States
 

Lifespan: The Miriam Hospital
Providence,  Rhode Island,  02906
United States
 

University of Chicago Cancer Research Center
Chicago,  Illinois,  60637-1470
United States
 

Memorial Regional Hospital Comprehensive Cancer Center
Hollywood,  Florida,  33021
United States
 

Mount Sinai Medical Center, NY
New York City,  New York,  10029
United States
 

Cape Fear Valley Health System
Fayetteville,  North Carolina,  28302-2000
United States
 

FirstHealth Moore Regional Hospital
Pinehurst,  North Carolina,  28374
United States
 

Veterans Affairs Medical Center - Asheville
Asheville,  North Carolina,  28805
United States
 

State University of New York - Upstate Medical University
Syracuse,  New York,  13210
United States
 

Queens Cancer Center of Queens Hospital
Jamaica,  New York,  11432
United States
 

North Shore University Hospital
Manhasset,  New York,  11030
United States
 

Memorial Sloan-Kettering Cancer Center
New York City,  New York,  10021
United States
 

Arthur G. James Cancer Hospital - Ohio State University
Columbus,  Ohio,  43210-1240
United States
 

UCSF Comprehensive Cancer Center
San Francisco,  California,  94115
United States
 

Ellis Fischel Cancer Center - Columbia
Columbia,  Missouri,  65203
United States
 

Walter Reed Army Medical Center
Washington D.C.,  District of Columbia,  20307-5000
United States
 

Lakeland Medical Center - St. Joseph
Saint Joseph,  Michigan,  49085
United States
 

Florida Hospital Cancer Institute
Orlando,  Florida,  32804
United States
 

Green Mountain Oncology Group
Bennington,  Vermont,  05201
United States
 

Cooper University Hospital
Camden,  New Jersey,  08103
United States
 

Comprehensive Cancer Center at Wake Forest University
Winston Salem,  North Carolina,  27157-1082
United States
 

Roswell Park Cancer Institute
Buffalo,  New York,  14263-0001
United States
 

Veterans Affairs Medical Center - Buffalo
Buffalo,  New York,  14215
United States
 

Northeast Alabama Regional Medical Center
Anniston,  Alabama,  36207
United States
 

Rebecca and John Moores UCSD Cancer Center
La Jolla,  California,  92093-0658
United States
 

Ministry Medical Group - Northern Region
Rhinelander,  Wisconsin,  54501
United States
 

West Suburban Center for Cancer Care
River Forest,  Illinois,  60305
United States
 

University of Massachusetts Memorial Medical Center - University Campus
Worcester,  Massachusetts,  01655
United States
 

Martha Jefferson Hospital
Charlottesville,  Virginia,  22901
United States
 

Veterans Affairs Medical Center - Las Vegas
Las Vegas,  Nevada,  89106
United States
 

Lineberger Comprehensive Cancer Center, UNC
Chapel Hill,  North Carolina,  27599-7295
United States
 

Veterans Affairs Medical Center - San Francisco
San Francisco,  California,  94121
United States
 

Baptist Hospital East - Louisville
Louisville,  Kentucky,  40207
United States
 

University of Minnesota Cancer Center
Minneapolis,  Minnesota,  55455
United States
 

Holden Comprehensive Cancer Center
Iowa City,  Iowa,  52242-1009
United States
 

Oncology and Hematology Associates of Southwest Virginia, Inc.
Roanoke,  Virginia,  24014
United States
 

St. Mary's Medical Center
Huntington,  West Virginia,  25701
United States
 

CCOP - Christiana Care Health Services
Newark,  Delaware,  19713
United States
 

Saint Anthony Medical Center
Rockford,  Illinois,  61108
United States
 

Helen and Harry Gray Cancer Institute at Good Samaritan Medical Center
West Palm Beach,  Florida,  33401
United States
 

Fort Wayne Medical Oncology and Hematology, Incorporated
Ft. Wayne,  Indiana,  46885-5099
United States
 

Veterans Affairs Medical Center - Baltimore
Baltimore,  Maryland,  21201
United States
 

CCOP - North Shore University Hospital
Manhasset,  New York,  11030
United States
 

Duke Comprehensive Cancer Center
Durham,  North Carolina,  27710
United States
 

Lenoir Memorial Hospital Cancer Center
Kinston,  North Carolina,  28503-1678
United States
 

Veterans Affairs Medical Center - White River Junction
White River Junction,  Vermont,  05009
United States
 

Lombardi Cancer Center
Washington D.C.,  District of Columbia,  20007
United States
 

Veterans Affairs Medical Center - Fargo
Fargo,  North Dakota,  58102
United States
 

Hematology Oncology Associates of the Quad Cities
Bettendorf,  Iowa,  52722
United States
 

NorthEast Oncology Associates
Concord,  North Carolina,  28025
United States
 

Broward General Medical Center
Ft. Lauderdale,  Florida,  33316
United States
 

Marlene and Stewart Greenebaum Cancer Center, University of Maryland
Baltimore,  Maryland,  21201
United States
 

Norris Cotton Cancer Center
Lebanon,  New Hampshire,  03756-0002
United States
 

Washington University School of Medicine
St. Louis,  Missouri,  63110
United States
 

CCOP - Syracuse Hematology-Oncology Associates of Central New York, P.C.
Syracuse,  New York,  13217
United States
 

Veterans Affairs Medical Center - Durham
Durham,  North Carolina,  27705
United States
 

Dana-Farber Cancer Institute
Boston,  Massachusetts,  02115
United States
 


Additional Information:
Study ID Numbers:
  CDR0000068140;  CLB-59906
Study Start Date: 
Record last reviewed: October 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00006125

Other Recurrent Grade Iii Follicular Large Cell Lymphoma Studies:
1. Combination Chemotherapy With or Without Rituximab in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

2. Monoclonal Antibody Therapy in Treating Patients With Recurrent Non-Hodgkin's Lymphoma

3. Paclitaxel and Estramustine in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

4. Ifosfamide, Teniposide, and Paclitaxel in Treating Patients With Relapsed Non-Hodgkin's Lymphoma

5. Rituximab and Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Related Studies:

Other recurrent grade III follicular large cell lymphoma Clinical Trials
Other North Carolina Clinical Trials
Other Pinehurst Clinical Trials

Combination Chemotherapy in Treating Patients With Relapsed or Refractory Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma

Modify your Search

  Other recurrent grade III follicular large cell lymphoma Clinical Trials
  Other North Carolina Clinical Trials
  Other Pinehurst Clinical Trials


Warning: include(/var/www/cgi-bin/traxis/counter.php) [function.include]: failed to open stream: No such file or directory in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103

Warning: include() [function.include]: Failed opening '/var/www/cgi-bin/traxis/counter.php' for inclusion (include_path='.:/usr/local/lib/php') in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103